Press Releases
ImmunoGen, Inc. Announces Positive Interim Results in Randomized Clinical Trial
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the reporting of positive interim clinical data with trastuzumab-DM1 (T-DM1) for...
Industry Reports
Cephalon Reports Record Sales – Quaterly sales increased 32% percent
Cephalon, Inc. reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter...
News
Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
Bexion Pharmaceuticals announced that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI)....
Drug Research
Newly Published Caldolor(R) Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
Cumberland Pharmaceuticals Inc. announced the publication of data affirming the safety and efficacy of Caldolor(R) (ibuprofen) Injection in treating fever in critically ill and...
News
Abbott Named One of the “Top Employers” in the Biotech and Pharmaceutical Industry by Science Magazine
Abbott Park, Illinois was named one of the top 20 employers in Science magazine's 2010 Top Biopharma Employers survey. The annual survey seeks to...
Drug Research
Scripps Research Study Challenges Conventional Theory of Modern Drug Design
Scientists from The Scripps Research Institute have uncovered new evidence that challenges the current theory about a process key to the way modern drugs...
Production & Manufacturing
Novartis announces agreement to develop influenza vaccines using revolutionary synthetic genomics technology
Novartis announced today an agreement with Synthetic Genomics Vaccines Inc. (SGVI) to apply "synthetic genomics" technologies to accelerate the production of the influenza seed...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
